Summary:
In patients following acute myocardial infarction (AMI), empagliflozin treatment significantly modulated sirtuin and microRNA expression, improving cardiac function recovery compared to placebo treatment over 26 weeks, though it was associated with no notable adverse effects reported in this analysis.
| PICO | Description |
|---|---|
| Population | 227 adult patients post-acute myocardial infarction (AMI), analyzed for changes in cardiac function and molecular biomarkers. |
| Intervention | Empagliflozin treatment over 26 weeks, investigating alterations in sirtuin gene (SIRT1–7) expression and specific microRNAs (miR-182-5p, miR-302a-3p). |
| Comparison | Placebo treatment over the same 26-week period, with baseline and follow-up biomarker and echocardiographic assessments. |
| Outcome | Empagliflozin led to increased SIRT6 and decreased SIRT4 expression, with higher predictive value for ΔLVEF <11% using a biomarker panel (SIRT2, SIRT4, miR-182-5p, miR-302a-3p). The combined panel achieved an AUC of 0.890 (81% sensitivity, 90% specificity) and remained significant after adjustment. Baseline NT-proBNP did not predict outcome. |
Source: Nowak-Szwed, Anna, et al. “Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction.” Read article here.
